简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Pharmacyte Biotech(OTCMKTS: PMCBD)交易价格上涨0.4%

2023-03-29 14:04

PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating)'s stock price traded up 0.4% during trading on Tuesday . The stock traded as high as $2.88 and last traded at $2.84. 33,197 shares changed hands during mid-day trading, an increase of 276% from the average session volume of 8,831 shares. The stock had previously closed at $2.83.

PharmaCyte Biotech Price Performance

The company's 50 day simple moving average is $2.94 and its 200 day simple moving average is $2.86.

PharmaCyte Biotech Company Profile

(Get Rating)

PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.

Featured Articles

  • Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
  • After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
  • Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
  • Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
  • The Bottom Is In For McCormick & Company
  • Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。